Biography
Eugenia Poliakov obtained her doctoral degree in Chemistry from the Case Western University, Chemistry Department, Cleveland, OH. She completed her postdoctoral training at the National Eye Institute, NIH. She joined LRCMB as staff scientist in November 2006. Her major scientific focus is beta-carotene oxygenases 1 and 2 and their role in carotenoid metabolism and vitamin A biosynthesis. She is focused on the design of small molecules inhibitors for carotene oxygenases and closely related RPE65 isomerase.
Lab Skills
HPLC, LC/MS/MS, MALDI-TOF, 1D and 2D gel electrophoresis, ELISA, protein purification, DNA isolation and cloning techniques, PCR, oligonucleotide-directed mutagenesis, cell culture.
Experience
2006- present
LRCMB, National Eye Institute, NIH Bethesda, MD
Staff scientist
Study the molecular mechanism of RPE65 retinol isomerase activity.
Investigate biochemistry and molecular biology of related beta-carotene monooxygenases. Research additional functions of -carotene monooxygenases for regulation of xanthophylls levels in the human macula.Mentor junior staff in the laboratory.
2001- 2006
LRCMB, National Eye Institute, NIH Bethesda,MD
Postdoctoral fellow (IRTA)
Developed activity assays for enzymes from polyene oxygenase family (BCMO1, BCMO2 and RPE65), studied its catalytic mechanisms and try to find crucial amino acid residues, which are necessary for their activity. Created mutant forms of BCMO1 and BCMO2 enzymes and run kinetic studies to compare their activity. Identified proteins using MALDI/TOF spectrometry. Applied HPLC for separation and quantification of retinoids and carotenoids.
Designed mass spectrometry methods for studying carotenoid metabolism in mice. Used Q-TOF instrument to quantify deuterium-labeled carotenoids and retinoids in mice tissues.
Mentored high-school students from a student internship program sponsored by Howard Hughes Medical Institute. Teached as part-time instructor “Introductory Biochemistry” in FAES graduate school (NIH)
1998 2001
Cleveland Clinic Foundation, Cleveland, OH
Research Assistant
Developed HPLC methods (LSD/UV detection) for separation of oxidized bioactive lipids. Identified a new class of the CD36 scavenger receptor ligands. Demonstrated that these oxidized phospholipids mediate internalization of LDL and development of atherosclerotic plaques. Used LC/MS to confirm presence of these “atherogenic” lipids in tissues in a rabbit model of atherosclerosis.
1996 2001
Case Western Reserve University, Cleveland,OH
Graduate Student
Synthesized authentic samples of lipid oxidation products and confirmed their presence in model oxidized vesicle systems by LC/MS. Demonstrated that these lipids could be used as biomarkers of oxidative stress in mouse model of inflammation.Analyzed oxidized LDL and plasma for the presence of lipid-modified proteins by immunoassay. Carried out studies of modified proteins by HPLC amino acid analysis.
1996-1997 Teaching Assistant (organic chemistry)
Supervised laboratory work of group of 10 students. Explained each experiment before start, helped with lab reports and graded results.
1995-1996
Institute of Molecular Biology, Moscow, Russia
Research Assistant
Developed DNA-constructs for cloning of multiunit eukaryotic genes.
Education
Case Western Reserve University, Cleveland, OH
08. 2001: Ph.D. in Chemistry.
Moscow State University, Moscow, Russia
06. 1996: B.S./M.S. in Chemistry.
Oral Presentations
Data blitz short talk (The best poster award) “Fenretinide is a potent noncompetitive inhibitor of BCMO1” Biology and Chemistry of Vision FASEB SRC 2009
Oral presentation: 7th Annual Meeting of the Oxygen Society. November 16-20, 2000. San Diego, California
Selected publications
“Biochemical evidence for the tyrosine involvement in cationic intermediate stabilization in mouse beta-carotene 15, 15’-monooxygenase”Poliakov E, Gentleman S, Chander P, Cunningham FX Jr, Grigorenko BL, Nemuhin AV, Redmond TM.BMC Biochem. 2009 Dec 14; (10):31.
“RPE65, visual cycle retinol isomerase, is not inherently 11-cis-specific: support for a carbocation mechanism of retinol isomerization”Redmond TM, Poliakov E, Kuo S, Chander P, Gentleman S.J Biol Chem. 2010 Jan 15; 285(3):1919-27. Epub 2009 Nov 17.
“Domain mobility in proteins: functional and evolutionary implications” Malay Basu MK, Poliakov E, Rogozin IBBriefings in Bioinformatics 2009 May; 10(3):205-16. Epub 2009 Jan 16.
“A Comprehensive Clinical and Biochemical Functional Study of a Novel RPE65 Hypomorphic Mutation” Birgit Lorenz, Eugenia Poliakov, Maria Schambeck, Christoph Friedburg, Markus N. Preising, and T. Michael RedmondInvest. Ophthalmol. Vis. Sci, 2008 49: 5235-5242.
“Effect of Leu/Met variation at residue 450 on isomerase activity and protein expression of RPE65 and its modulation by variation at other residues” Redmond T.M., Weber C.H., Poliakov E., Yu S., Gentleman S., Mol. Vis. 2007, 13:1813-1821
“Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype”Eugene A Podrez, Tatiana V Byzova, Maria Febbraio, Robert G Salomon, Yi Ma, Manojkumar Valiyaveettil, Eugenia Poliakov, Mingjiang Sun, Paula J Finton, Brian R Curtis, Juhua Chen, Renliang Zhang, Roy L Silverstein & Stanley L Hazen., Nature Medicine, August 26, 2007.
“Identification of a KRAB zinc-finger protein binding to the Rpe65 gene promoter”Lu Z, Poliakov E., Redmond T.M., Current Eye Research, 2006, 31:457-466.
“Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle.”Redmond TM, Poliakov E, Yu S, Tsai JY, Lu Z, Gentleman S.Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13658-63.
“Key Role of histidines in mouse beta-carotene 15,15’-monooxygenase activity.” Eugenia Poliakov, Susan Gentleman, Francis X. Cunningham, Nancy J. Miller-Ihli and T.Michael Redmond.. J Biol Chem. 2005 Aug 12;280(32):29217-23.
“Iso[7]LGD2-protein adducts are abundant in vivo and free radical-induced oxidation of an arachidonyl phospholipids generates this D-series isolevuglandin in vitro.” Eugenia Poliakov, Susan Gillette Meer, Subhas C. Roy, Clementina Mesaros, and Robert G. Salomon. Chem Res Toxicol. 2004 May;17(5):613-22.
“Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo.” Poliakov E, Brennan ML, Macpherson J, Zhang R, Sha W, Narine L, Salomon RG, Hazen SL. FASEB J. 2003 Dec;17(15):2209-20
“Identification of a Novel Family of Oxidized Phospholipids That Serve as Ligands for the Macrophage Scavenger Receptor CD36.” Podrez EA, Poliakov E, Shen Z. J Biol Chem. 2002 Oct 11;277(41):38503-38516.
“A Novel Family of Atherogenic Oxidized Phospholipids Promotes Macrophage Foam Cell Formation via the Scavenger Receptor CD36 and Is Enriched in Atherosclerotic Lesions.” Podrez EA, Poliakov E et al. J Biol Chem. 2002 Oct 11;277(41):38517-38523.
“Novel bioactive phospholipids: practical total syntheses of products from the oxidation of arachidonic and linoleic esters of 2-lysophosphatidylcholine.” Sun M, Deng Y, Batyreva E, Sha W, Salomon RG. J. Org. Chem. 2002 May 31;67(11):3575-84.
“Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway.” Robert G. Salomon, Eugenia Batyreva, Kamaljit Kaur et al. Biochim. Biophys. Acta, 2000, 1485:225-235.
“Isolevuglandin-protein adducts in oxidized Low-density Lipoprotein and Human plasma.” Robert G. Salomon, Kamaljit Kaur and Eugenia Batyreva. Trends Cardiovasc. Med. 2000 10: 53-59.